Skip to content

H.R. 198 · 118th Congress (2023–2025)

Drug Pricing Transparency and Accountability Act

This bill establishes a two-year moratorium on allowing new, non-rural hospitals and associated child sites to participate in the 340B drug pricing program; during the moratorium, the Department of Health and Human Services must issue regulations with specified program eligibility standards. The bill also requires additional reporting relating to program participation, eligibility, and costs.

Show official title

To increase reporting requirements and transparency requirements in the 340B Drug Pricing Program, and for other purposes.

Expired in House committee

Derived from the legislative history, not an official disposition.

Latest actionReferred to Health

This bill’s path

This is H.R. 198’s recorded path, not a universal congressional workflow.

How bills become lawAll actions
  1. Introduced

  2. Passed House

  3. Passed Senate

  4. Sent to President

  5. Signed into law

  6. Expired

Sponsor
Rep. Matthew M. Rosendale Sr. (R-MT-2)
Policy area
Health
Subjects
  • Administrative law and regulatory procedures
  • Congressional oversight
  • Department of Health and Human Services
  • Government information and archives
  • Government studies and investigations
  • Health facilities and institutions
  • Health information and medical records
  • Home and outpatient care
  • 7 more
    • Hospital care
    • Medicaid
    • Medicare
    • Prescription drugs
    • Public contracts and procurement
    • Public-private cooperation
    • State and local government operations

On this page

Timeline

i

In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.

  1. Introduced in House

    Document: Introduced in House

    Sources
  2. Latest
    ▸ 3 committee actions · Jan 9, 2023 – Dec 17, 2024
    1. Referred to committee

      Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

      Sources
    2. Referred to Health

      Referred to the Subcommittee on Health.

      Sources
    3. Referred to Health

      Referred to the Subcommittee on Health.

      Sources
  3. Expired

    Introduced → Referred to House Health → No further action before the 118th Congress ended.

Committees

  1. HouseEnergy and CommerceReferred Jan 9, 2023
  2. HouseHealthReferred Jan 20, 2023
  3. HouseWays and MeansReferred Jan 9, 2023
  4. HouseHealthReferred Dec 17, 2024

Text & titles

i

Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.

Text versions
VersionDateLinks
Introduced in House
Titles (2)
  1. Drug Pricing Transparency and Accountability Act

    Display title, Short title · Introduced in House

  2. To increase reporting requirements and transparency requirements in the 340B Drug Pricing Program, and for other purposes.

    Official title · Introduced in House